跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
radiotherapeutics
首页
药物
radiotherapeutics
radiotherapeutics
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY
EP 3536345 A1
申请人: UNIV JOHNS HOPKINS
优先权: 2014
CN
EP
US
WO
10 件公开
IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING FIBROBLAST-ACTIVATION PROTEIN- (FAP- )
EP 3700580 A4
申请人: UNIV JOHNS HOPKINS
优先权: 2017
CN
EP
US
WO
10 件公开
RADIOTHERAPEUTIC MICROSPHERES
EP 3972566 A4
申请人: UNIV TEXAS
优先权: 2019
CN
EP
US
3 件公开
FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF
EP 4598928 A1
申请人: RADIONETICS ONCOLOGY INC
优先权: 2022
EP
US
WO
3 件公开
GONADOTROPIN-RELEASING HORMONE RECEPTOR (GNRHR) TARGETED THERAPEUTICS AND USES THEREOF
EP 4634174 A1
申请人: RADIONETICS ONCOLOGY INC
优先权: 2022
EP
US
WO
3 件公开
Neuropeptide Y1 receptor (NPY1R) targeted therapeutics and uses thereof
US 12685789 B2
申请人: RADIONETICS ONCOLOGY INC
优先权: 2023
US
WO
3 件公开
Kisspeptin receptor (KISS1R) targeted therapeutics and uses thereof
US 12521455 B2
申请人: RADIONETICS ONCOLOGY INC
优先权: 2024
US
WO
3 件公开
NEUROTENSIN RECEPTOR 1 (NTSR1) TARGETED THERAPEUTICS AND USES THEREOF
US 20260207797 A1
申请人: RADIONETICS ONCOLOGY INC
优先权: 2024
US
WO
2 件公开
Modulators of the megalin-mediated uptake of radiotherapeutics and/or radiodiagnostics into kidney cells and their use in therapy and diagnostics
EP 1462119 A1
申请人: SCHERING AG
优先权: 2003
EP
Modulator of the megalin-mediated uptake of radiotherapeutics and/or radiodiagnostics into kidney cells and their use in therapy and diagnostics
US 2004204357 A1
申请人: BRAUTIGAM MATTHIAS
优先权: 2004
US
第 1 / 2 页
上一页
下一页
药物
反馈